Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials ; volume:24 ; number:1 ; day:18 ; month:12 ; year:2024 ; pages:1-11 ; date:12.2024
BMC gastroenterology ; 24, Heft 1 (18.12.2024), 1-11, 12.2024
- Urheber
-
Wang, Zhenzi
Liu, Yuan
Wang, Kedi
Ma, Liyan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12876-024-03554-8
- URN
-
urn:nbn:de:101:1-2503010622305.282204551503
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wang, Zhenzi
- Liu, Yuan
- Wang, Kedi
- Ma, Liyan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Comparing VIP and PD‐L1 expression as cancer biomarkers
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Regulatory mechanisms of PD-1/PD-L1 in cancers
The PD-1:PD-L1 axis in Inflammatory Arthritis
PD-1/PD-L1 binding studies using microscale thermophoresis
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
Comparing VIP and PD‐L1 expression as cancer biomarkers
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Regulatory mechanisms of PD-1/PD-L1 in cancers
The PD-1:PD-L1 axis in Inflammatory Arthritis
PD-1/PD-L1 binding studies using microscale thermophoresis
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
Comparing VIP and PD‐L1 expression as cancer biomarkers
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Regulatory mechanisms of PD-1/PD-L1 in cancers
The PD-1:PD-L1 axis in Inflammatory Arthritis
PD-1/PD-L1 binding studies using microscale thermophoresis
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer